In this article, we will take a look at 10 High Growth European Stocks To Buy.
European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a flood of significant company earnings. While concerns over President Donald Trump’s controversial position on Greenland and the possibility of a trade dispute between the European Union and the United States have subsided, global tensions remain high.
The Stoxx 600 index surged 0.6% to 613.11 points on January 27. Meanwhile, Germany’s DAX index dropped 0.10% to 24,908.23 points, while France’s CAC 40 index rose 0.27% to 8,152.82 points. The improvements show how investors rely on company-specific factors to steer the market in an increasingly unpredictable economic climate.
Additionally, the European Union and India signed a deal on a free trade pact on the same day, the largest of its kind ever signed by either side, as they grapple with an unpredictable trade policy from the United States. While financial stocks had a particularly stellar session following the deal, automakers were widely down as the agreement reduced car tariffs from 110% to 10% for 250,000 vehicles per year. Speaking on the growth of bank stocks, Ciaran Callaghan, head of European equity research at Amundi, said the following:
“The fundamentals for banks have really improved. We expect loan growth to pick up, and we could see further positive earnings surprises from the sector this year.”
Our Methodology
Our selection criteria focused on European stocks with a 5-year revenue growth rate of (at least 20%), thus indicating solid growth. In addition, we ranked these stocks based on the number of hedge funds invested in each of them as of Q3 2025.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. Genmab A/S (NASDAQ:GMAB)
5-Year Revenue Growth Rate: 31.15%
Number of Hedge Fund Holders: 20
Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found no meaningful improvement in the overall survival for EPKINLY (epcoritamab) monotherapy when compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) patients.
Regardless of this shortcoming, H.C. Wainwright believes EPKINLY will likely maintain its 2023 accelerated clearance for third-line DLBCL treatment, at least until the results of two additional ongoing Phase 3 trials are released. In this context, the firm referenced a precedent set by Roche’s Columvi, which retained its accelerated approval despite missing overall survival targets in a similar patient group while expecting more study findings.
Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and EPKINLY.
Hedge Fund Resource Center